Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

23.46 -13.24 (-36.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
From Summit Therapeutics Inc.
Via Business Wire
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
From Summit Therapeutics Inc.
Via Business Wire
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
From Summit Therapeutics Inc.
Via Business Wire
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
Exposures Death
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
From Summit Therapeutics Inc.
Via Business Wire
H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
From Summit Therapeutics Inc.
Via Business Wire
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab Updated Data to be Featured at ASCO 2023
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
From Summit Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.